CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R

You-Shun Zhang, Fang-Jun Yuan, Guo-Feng Jia, Ji-Fa Zhang, Li-Yi Hu, Ling Huang, Ju Wang, Zong-Qing Dai

AIM: To investigate the cytotoxicity of the cytokine-induced killer (CIK) cells from the post-operation patients with primary hepatocellular carcinoma (HCC) to multidrug-resistant (MDR) cell of HCC both in vitro and in vivo.

METHODS: A drug-resistant cell line was established by culturing human HCC cell line Bel-7402 in complete RPMI 1640 medium with increasing concentrations of adriamycin from 10 to 2 000 nmol/L. CIK cells were obtained by inducing the peripheral blood mononuclear cells with rhIFN-γ, monoclonal anti-CD3 antibody, rhIL-1α as well as rhIL-2, which were added into the culture. To detect the cytotoxicity of the CIK cells from HCC patients, the Bel-7402/R was taken as target (T) cells and CIK cells as effect (E) cells. Cytotoxic test was performed and measured by MTT. As to in vivo test, CIK cells were transfused into patients with HCC. The tumor specimens of the patients were obtained and immunohistochemistry was carried out to detect CD3, CD45, CD45RO as well as CD68.

RESULTS: A MDR 1 HCC cell line Bel-7402/R was established. Its MDR1 mRNA overexpressed which was shown by RT-PCR; the P-glycoprotein expression increased from 1.32% of parent cells to 54%. CIK cells expanded vigorously by more than 70-fold and the CD3+CD56+ increased by more than 600-fold after 3-wk incubation on average. The cytotoxicity of CIK from HCC patients to Bel-7402/R was about 50% and to L-02 below 10% (t = 8.87, P<0.01), the same as that of CIK from normal individuals. Each of the 17 patients received 1-5×10⁵ of CIK cell transfusion. No side effects were observed. After CIK treatment, the tumor tissue nodules formed and a large amount of lymphocytes infiltrated in the liver cancer tissue and CD3, CD45, CD45RO, and CD68 increased greatly which was shown by immunohistochemistry.

CONCLUSION: A stable MDR1 HCC cell line has been established which could recover from liquid nitrogen and CIK from HCC patients has strong cytotoxicity to MDR HCC cell. CIK adoptive immunotherapy is safe and has no side effects. Receivers improved their immunity to tumor evidently. CIK treatment may be a better choice for HCC patients after operation to prevent the recurrence, especially when tumors have developed drug resistance.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Hepatocellular carcinoma; Cytokine-induced killer; Cytotoxicity; Multidrug resistance; P-glycoprotein

Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, Wang J, Dai ZQ. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005; 11(22): 3339-3345
http://www.wjgnet.com/1007-9327/11/3339.asp

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high mortality especially in China because of wide prevalence of HBV infection. Surgical operation is still the most effective and widely performed treatment, but the high frequency of recurrence after operation dramatically decrease the cure rate of HCC. To prevent recurrence of HCC, many measures have been taken such as regular chemotherapy after operation, intrahepatic arterial infusion of anticancer agents, transcutaneous arterial embolization and recently, biotherapy[4-6] such as DC[7] cells and cytokine-induced killer (CIK) cells[8]. However, many patients’ prognosis is poor and the 5-year survival rate usually is below 15-30%. Besides other reasons, drug resistance of the tumors induced in the chemotherapy plays an important role, which in turn protects the tumors against the chemical agents[9]. Among the many known biological mechanisms of drug resistance, multidrug resistance (MDR) is of particular interest[10,11]. MDR is associated with amplification or overexpression of the MDR1 gene and the expression of a transmembrane glycoprotein of 170 ku termed P-glycoprotein (Pgp). As a drug pump, it excludes the chemical drugs out of tumor cells and causes treatment failure.

CIK cells are generated according to a novel protocol[12] and several authors[13-15] have demonstrated that CIK possesses versatile anti-tumor advantages including easier generation from T cells, stronger cytotoxicity to tumor as well as more enhanced in vivo proliferation potency while compared with other adoptive immunotherapies. Shi et al,
and Wang et al., demonstrated that CIK treatment for HCC is effective and also safe. Now we show in this paper that multi-drug resistant HCC cell line Bel-7402/R, established by us, is also sensitive to CIK from HCC patients and positive pathological and immunohistochemical results were observed in one case whose tumor sample was verified as positive MDR1 expression by RT-PCR.

MATERIALS AND METHODS

Patients and controls

Seventeen HCC patients post-operation were enrolled in the study, including 16 cases of male and 1 female, aged 36-58 years with an average of 48.8 years. A written informed consent was obtained before CIK treatment which was certified by the Health Bureau of Hubei Province, China. Six of the patients were chosen randomly to take part in the in vitro test and six normal people from hospital staff were selected as normal controls.

Cell lines and culture conditions

All cell lines were grown\(^{[9]}\) in complete medium (CM) namely RPMI 1640 (Gibco) with 100 mL/L calf serum, 25 mmol/L L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 50 μmol/L 2-mercaptoethanol (2-ME, all from Sigma). Some other agents were added according to research needs. Human HCC cell line Bel-7402 was a generous present from Professor Guanxin Shen, Department of Immunology, Tongji Medical School, Huazhong Science and Technology University. HCC cell line SMMC-7721 and embryo liver cell line L-02 were provided by the China Center for Type Culture Collection. Drug-resistance cell lines Bel-7402/R as well as SMMC-7721/R were induced by serially increasing adriamycin (ADM, Sigma) from 10 to 2 000 nmol/L in the culture.

CIK induction

CIK cells were prepared as described according to Schmidt-Wolf\(^{[10]}\). Briefly, for in vitro treatment peripheral blood mononuclear cells (PBMCs) were collected by CS-3000 Plus blood cell separator (Baxter, USA) or for in vitro test prepared by ficoll separation from post-operation patients with HCC (HCC group) or from volunteers as control group (normal group). The cells were grown in CM and 1 000 U/mL rhIFN-γ was added on d 0, after 24 h of incubation, 50 μg/L mouse monoclonal antibody (mAb) against CD3, 100 U/mL rhIL-1α (all from R&D Systems) and 1 000 U/mL rhIL-2 (Sunshine Pharma. Co., Ltd, China) were added. Cell density was about 1×10^6/mL and fresh CM with IL-2 was replaced every 3 d. Cell phenotypes were identified by FCM on d 0, 7, 14, 25. Cytotoxicities to target were determined after d 14. Cells were transfused back to patients between d 14 and 21 based on the cell number.

RT-PCR

Primers for MDR1 RT-PCR were designed based on the sequence in GenBank (NM000927), forward primer 5’-CAGGAGATAGGCTGTTTGATG T-3’ and backward primer 5’-TTAGCTTCCAACCACG TGTAATC-3’. PCR was performed according to molecular cloning protocol, briefly as follows: after the collection of cultured cells or mincing of HCC tissue into small pieces, RNA was extracted by TRIzol reagent. Extracted RNA was solved in diethyl pyrocarbonate-treated water (DEPC water). RT-PCR was performed in 50 μL of mixture containing: 1 μL of extracted RNA, 1 μL of 10 μmol/L of both forward and backward primers (synthesized by Sangon, Shanghai, China), 5 μL of 10× buffer (100 mmol/L of Tris-HCl, pH 8.0, 500 mmol/L of KCl, 0.1% gelatin, 1% Triton X-100), 1 μL of 10 mmol/L dNTP, 4 μL of 25 mmol/L MgCl2, 2.5 U of ribonuclease inhibitor, 200 U of M-MLV RT enzyme, 2 U of Taq polymerase, and DEPC water was added to the final volume of 50 μL. The reaction mixture was kept at 42 °C for 30 min to synthesize first cDNA, and at 94 °C×3 min to denature DNA followed by 35 cycles of amplification consisting of 30 s of denaturing DNA at 94 °C, 30 s of annealing DNA at 58 °C and 30 s of extending DNA at 72 °C. β-actin served as control.

Flow cytometry analysis

All samples were pretreated before analyzed by FCM analyzer (Coulter: EPICX XL). For cell phenotype identification, cells were incubated for 30 min with mAb against CD3, CD4, CD56, coupled to FITC or PE. For the detection of Pgp, cells were fixed with 4% paraformaldehyde for 10 min, incubated with mouse anti-human p-170 for 30 min at room temperature, and stained with goat antimouse IgG coupled to FITC. For Pgp function determination\(^{[15]}\), cells were incubated with Rhodamine 123 (Sigma) for 1 h before being trypsinized and washed.

Drug-resistance test

One hundred microliters of each parent or drug-resistant cells were distributed in 96-well culture microplates at 1×10^4/mL density in every well. ADM was added after a serial dilution from 40 μmol/L to 36.25 mmol/L. A triplicate of same samples was placed to control variation. Cells were incubated at 37 °C with 50 mL/L CO2 for 48 h prior to the addition of 10 μL of MTT\(^{[18,20]}\) (5 g/L Sigma). After another 4 h of incubation, the plate was centrifuged at 3 000 r/min for 5 min, medium was discarded, 150 μL of DMSO was added to each well. Optical absorbance value was read at 570 nm by a microreader (BioRad 550, USA). Cell survival ratio (CSR) was calculated according to the formula: CSR = A_{570 \text{ experiment}}/A_{570 \text{ control}}×100%. The 50% inhibition concentration (IC50) was determined by concentration-CSR curve.

Cytotoxicity test

One hundred microliters of target cells were seeded in a microplate at a 1×10^4/mL density and 0.1 mL of effect cells at a 1×10^5/mL density were mixed into each well (to reduce the influence of effect cell number, we deliberately made the E:T = 10:1). After 4 h of incubation, 10 μL of MTT was added. And following treatments were the same as in drug -resistant test. Cytotoxicity rate (CR) was calculated by the following formula: CR = [1- (A_{570 \text{ experiment}}/A_{570 \text{ control}})] ×100%.
Immunohistochemistry
Specimens were HE stained and observed under a microscope. Cell markers were demonstrated by immunohistochemistry according to S-P protocol on slides with mAb against CD3, CD45, CD45RO, CD68 (Neomarker) as first antibody, goat anti-mouse antibody as second antibody.

Statistical analysis
Analysis was performed by using Student’s t test, the data were expressed as mean±SD and P<0.05 was considered statistically significant.

RESULTS
Generation of CIK from PBMCs
The proliferation and phenotype of the PBMCs after CIK induction varied according to individual HCC patients. The cell number increase was more than 70-fold on average \((n=17)\) after 25-d incubation. CD3+CD56+ cells increased greatly by about 60-fold to more than 1400-fold with an average of more than 600-fold (Table 1).

Induction of drug-resistant HCC cells
Bel-7402 HCC cell line under went drug-resistant induction test beginning with 10 nmol/L of ADM in the medium increased gradually to 200 or 2000 nmol/L. Cells showed a series of changes (Figure 1) such as enlarged, polynuclear, discontinuous in plasma membrane (Figure 1B). Most of them died then some “normal” cell islands (Figure 1C) appeared, the same as the parent cell (Figure 1A). We designated the induced cells which survived in 200 nmol/L of ADM as Bel-7402/R-200, and those survived in 2000 nmol/L of ADM, as Bel-7402/R-2000. After both grew in 2 mmol/L of ADM for 1 h, most of the former died and most of the latter still survived, indicating there might be some difference between the two. When MTT test was done to the parent cell and both drug-resistant cells, they showed different IC\(_{50}\) with ADM. IC\(_{50}\) of the parent Bel-7402 was 42 nmol/L, and of the induced cells, 2000 and 8000 nmol/L respectively (Figure 2). RT-PCR showed MDR1 overexpressed in induced cells and the parent cells generally gave negative results. Intracellular concentration of Rhodamine 123 was also determined by FCM (Figure 3), since Rhodamine 123 produces fluorescence itself and would be pumped out of cells if the Pgp existed. Bel-7402/R cells kept only 25.1%, 28.4% of Rhodamine 123 intracellularly each and the parent Bel-7402, 77.7%. Stained with anti-P-170 mAb (Figure 4), and determined by FCM, we found that only 1.32% of parent cells expressed P-170 and Bel-7402/R increased to 47%, 54% respectively.

Different from other reports, although it showed similar characters to Bel-7402/R in drug-resistance, the SMMC-7721/R only endured a smaller range of drug concentration (below 100 nmol/L of ADM) and it was difficult to recover from liquid nitrogen keeping.

Table 1 Determination of CD3CD56 of CIK cells \((n=6)\)

|         | CD3+(%) | CD3+CD56+(%) |
|---------|---------|-------------|
| Normal  | 59.5±7.8 | 3.2±1.6     |
| HCC     | 45.1±12.1| 2.4±2.1     |
|         | 93.3±6.5 | 20.6±13.4   |
|         | 89.4±5.1 | 19.1±11.7   |

\(^*P<0.05\) vs others.
Cytotoxicity of CIK to drug-resistant HCC cells

Shi et al. and Wang et al. have proven the CIK cells from HCC patients have stronger cytotoxicity to HCC cells and here we found that CIK both from normal persons and HCC patients had similar cytotoxicity to drug-resistant HCC cells (Figure 5) at different E:T ratios, so we chose E:T = 10:1 to avoid bias produced by effect cell number in the test. The experiment wells contained $10^4$ target cells mixed with $10^5$ effect cells. Effect control (E control) included $10^5$ effect cells only and target control (T control), $10^4$ target cells only. Cytotoxicity of CIK from HCC patients to Bel-7402/S was 33-68% with an average of 50.7%. While to Bel-7402/R it was 37-64% with an average of 52.3% ($P > 0.05$), the same as normal group. Cytotoxicity CIK from HCC patients to L-02, an embryo liver cell line, was under 10%, indicating no side effect to normal liver cells (Tables 2 and 3).

Cytotoxicity of CIK to drug-resistant HCC cells

Seventeen cases of recurrent HCC patients post-operation were recruited into our study, most of them with relapsed bulk tumors and no effective treatment. The results showed that CIK treatment for HCC was safe, effective, without side effects (data reported elsewhere). Here we only focus on one case whose tumor had been demonstrated MDR1 overexpression by RT-PCR and immunohistochemistry assay.

**Table 2** Results of cytotoxicity of CIK to target cells

| Patient Number | 7402/s (%) | 7402/R (%) | L-02 (%) | E control |
|----------------|------------|------------|----------|-----------|
| 1              | 0.802 (33) | 0.743 (49) | 1.011 (12)| 0.485     |
| 2              | 0.913 (48) | 0.895 (47) | 1.201 (4) | 0.627     |
| 3              | 0.681 (46) | 0.599 (57) | 0.888 (14)| 0.379     |
| 4              | 0.630 (68) | 0.602 (60) | 0.959 (7) | 0.401     |
| 5              | 0.711 (58) | 0.802 (37) | 1.001 (12)| 0.479     |
| 6              | 0.987 (51) | 0.933 (64) | 1.302 (2) | 0.718     |
| T control      | 0.554      | 0.508      | 0.595     |

$t_{1,6} = 8.70, \ P < 0.01$ $t_{1,5} = 8.87, \ P < 0.01$

**Table 3** Average of cytotoxicity and significance of difference ($n = 6$)

| 7402/s (%) | 7402/R (%) |
|------------|------------|
| HCC        | 50.7       |
| Normal     | 57.1       |

$P > 0.05$ (not significant)

**Figure 3** Rhodamine 123 excluding test detected by FCM. A: Control; B: Bel7402/r-2000; C: Bel7402/r-200; D: Bel7402/S.

**Figure 4** Indirect immunofluorescence on Pgp detected by FCM. A: Bel7402/s; Bel7402/r-200; C: Bel7402/r-2000. B: Bel7402/r-200; C: Bel7402/r-2000.

**Figure 5** Cytotoxicity of CIK to Bel-7402 at different E:T ratios.

**In vivo effect of CIK**

Seventeen cases of recurrent HCC patients post-operation were recruited into our study, most of them with relapsed bulk tumors and no effective treatment. The results showed that CIK treatment for HCC was safe, effective, without side effects (data reported elsewhere). Here we only focus on one case whose tumor had been demonstrated MDR1 overexpression by RT-PCR and immunohistochemistry assay.
before and after operation was carried out. The patient was a male, 56 years old, relapsed about one year after liver tumor resection with pneumal metastasis and cancer embolus in portal vein, and received CIK treatment. After transfused $1.3 \times 10^{10}$ CIK cells, the patient had improvement of nausea, vomiting and the windy abdomen, as well as his appetite. His ascites abated too. After another 3 mo a second operation was performed and the tumor sample underwent pathological and immunohistochemical assay. Compared with the specimen before CIK treatment the tumor became

**Figure 6** Immunohistochemistry results of the tumor specimen before and after CIK treatment, demonstrated that a large amount of lymphocytes with CD3, CD45, CD45RO, CD68 markers infiltrated in tumor after treatment. **A**: Immunohistochemistry with anti-CD3 to the specimen before treatment; **B**: with anti-CD3 to the specimen after treatment; **C**: immunohistochemistry with anti-CD45 to the specimen before treatment; **D**: with anti-CD45 to the specimen after treatment; **E**: immunohistochemistry with anti-CD45RO to the specimen before treatment; **F**: with anti-CD45RO to the specimen after treatment; **G**: immunohistochemistry with anti-CD68 to the specimen before treatment; **H**: with anti-CD68 to the specimen after treatment.
noodular with a large amount of lymphocytes infiltration after treatment (Figure 6). CD3, CD45, CD45RO, CD68 positive cells increased vigorously (Table 4 and Figure 6) to 41, 283, 44, 77/HPF each from 0.1, 15, 3, 8/HPF before CIK treatment indicating the anti-tumor immunity was enhanced significantly since CD3, CD45 represent T cells, CD45RO is the marker of T memory subset, while CD68 is the marker of mono/macrophage.

It is interesting that while CIK kills the tumor cells vigorously it has little effect on L-02 cells. Similar results were reported by Schmidt-Wolf et al.[20,21]. They found that despite high cytotoxic activity of CIK against lymphoma cells, they had little toxicity against a subset of normal human hematopoietic progenitor cells. Some difference between Bel-7402 and L-02 has been reported recently by Shao et al.[20], that LAPTM4B, a newly found HCC related antigen, was expressed in Bel-7402 but not in L-02. A polyclonal antibody against LAPTM4B has been produced. Monoclonal antibody against it is in process of production. It may be helpful to solve the problem.

**Table 4** Comparison of immune cells in immunohistochemistry

|       | CD45 | CD3 | CD45RO | CD68 |
|-------|------|-----|--------|------|
| 1     | 15.4 | 0.15| 2.9    | 8.0  |
| 2     | 283  | 41.3| 44.1   | 77.7 |
| x-fold| 18.4 | 275 | 15.2   | 9.7  |

1: before treatment. 2: after treatment. HPF: high power field.

**DISCUSSION**

Other than transgene models, several drug-resistant HCC cell lines induced by ADM have been established[17-19]. In our laboratory, we found that Bel-7402 is easier and has a wider range in drug-dose to induce drug-resistance than smmc-7721, as the latter is difficult to grow in >100 nmol/L wide range in drug-dose to induce drug-resistance than our laboratory, we found that Bel-7402 is easier and has a cell lines induced by ADM have been established

Table of immune cells in immunohistochemistry

|       | CD45 | CD3 | CD45RO | CD68 |
|-------|------|-----|--------|------|
| 1     | 15.4 | 0.15| 2.9    | 8.0  |
| 2     | 283  | 41.3| 44.1   | 77.7 |
| x-fold| 18.4 | 275 | 15.2   | 9.7  |

1: before treatment. 2: after treatment. HPF: high power field.

CD45RO is the marker of mono/macrophage.

**REFERENCES**

1. Zhang YS, Dai ZQ. Advances in Hepatoma Biotherapy Research. Zhongguo Xian Dai Putong Waik Mei Jzhuan 2001; 4: 193-198
2. Kline NE. Promoting patient safety through the development of a pediatric chemotherapy and biotherapy provider program. J Pediatr Oncol Nurs 2004; 21: 65-66
3. Tan GH, Wei YQ, Tian L, Zhao X, Yang L, Li J, He QM, Wu Y, Wen YJ, Yi T, Ding ZY, Kan B, Mao YQ, Deng HX, Li HL, Zhou CH, Fu GH, Xiao F, Zhang XW. The mechanism of resistance of tumors with a recombinant xenogeneic endogin as a model antigen. Eur J Immunol 2004; 34: 2012-2021
4. Rice AM, Jones KL, Hart DN. DC preparations for therapy. Cytotherapy 2004; 6: 99-104
5. Hongseong S, Petissens S, Warapongpaiboon S, Rerkmaunyachoke B, Pakakasama S, Jootar S. Generation of CD3+ CD56+-cytotoxic-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003; 77, 175-179
6. Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol Med 2002; 8: 318-325
7. van Brussel JP, van Steenbruggue GJ, Romijn JC, Schroder FH, Mickisch GH. Cytomegalias of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35: 664-671
8. Warmann S, Golring R, Teichmann B, Geerlings H, Pletsch T, Fuchs J. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anti-cancer Res 2003; 23: 4607-4611
9. Schmidt-Wolf GF, Negrin RS, Kiern MP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149
10. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997; 74: 51-56
11. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-1679
12. Kaneko T, Fusauch Y, Kayuk Y, Okumura K, Mizoguchi H, Oshimi K. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk Lymphoma 1994; 14: 219-229
13. Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 1995; 86: 3493-3499
14. Zhang YX, Huang L, Yuan FJ, Wang B, Dai ZQ. Research on effects of tumor vaccine to mouse hepatocellular carcinoma. Yunyang Yixueyuan Xuebao 2002; 8: 18-22
15. Shapiro AB, Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl 1998; 643: 227-234
16. Zhang YS, Yao L, Huang L, Wang B, Dai ZQ. Observation on cytotoxicity of CD3AK. Yunyang Yixueyuan Xuebao 1999; 18: 200-201
17. Nakajima A, Yamamoto Y, Taura K, Hata K, Fukamoto M, Uchinami H, Yonezawa K, Yamaoka Y. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol 2004; 24: 635-645
18. He L, Liu GQ. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin 2002; 23: 591-596
19. Chu TM, Lin TH, Kawinski E. Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun 1994; 203: 506-512
20. Schmidt-Wolf IG, Finke S, Trojanek B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81: 1009-1016
21. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222
22. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rucker A, Sauerbruch T, Schmidt-Wolf IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunotherapy 2001; 24: 502-510
23. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993; 81: 1607-1613
24. Gold JE, Zachary DT, Osband ME. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Int J Cancer 1995; 61: 580-586
25. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996; 169: 85-90
26. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX. Molecular cloning and characterization of LAPTMB, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003; 22: 5060-5069